162 related articles for article (PubMed ID: 33042017)
1. β-arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation.
Czogalla B; Partenheimer A; Jeschke U; von Schönfeldt V; Mayr D; Mahner S; Burges A; Simoni M; Melli B; Benevelli R; Bertini S; Casarini L; Trillsch F
Front Endocrinol (Lausanne); 2020; 11():554733. PubMed ID: 33042017
[TBL] [Abstract][Full Text] [Related]
2. β-arrestins regulate gonadotropin receptor-mediated cell proliferation and apoptosis by controlling different FSHR or LHCGR intracellular signaling in the hGL5 cell line.
Casarini L; Reiter E; Simoni M
Mol Cell Endocrinol; 2016 Dec; 437():11-21. PubMed ID: 27502035
[TBL] [Abstract][Full Text] [Related]
3. G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients.
Fraungruber P; Kaltofen T; Heublein S; Kuhn C; Mayr D; Burges A; Mahner S; Rathert P; Jeschke U; Trillsch F
Front Endocrinol (Lausanne); 2021; 12():564002. PubMed ID: 33679613
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
5. Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients.
Deuster E; Mayr D; Hester A; Kolben T; Zeder-Göß C; Burges A; Mahner S; Jeschke U; Trillsch F; Czogalla B
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31212758
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into β-arrestin-dependent ERK signaling.
Liu H; Zhang Q; Li K; Gong Z; Liu Z; Xu Y; Swaney MH; Xiao K; Chen Y
Oncotarget; 2016 Dec; 7(49):81223-81240. PubMed ID: 27835898
[TBL] [Abstract][Full Text] [Related]
7. Reduced Gonadotrophin Receptor Expression Is Associated with a More Aggressive Ovarian Cancer Phenotype.
Cheung J; Lokman NA; Abraham RD; Macpherson AM; Lee E; Grutzner F; Ghinea N; Oehler MK; Ricciardelli C
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374698
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
9. Role of Increased n-acetylaspartate Levels in Cancer.
Zand B; Previs RA; Zacharias NM; Rupaimoole R; Mitamura T; Nagaraja AS; Guindani M; Dalton HJ; Yang L; Baddour J; Achreja A; Hu W; Pecot CV; Ivan C; Wu SY; McCullough CR; Gharpure KM; Shoshan E; Pradeep S; Mangala LS; Rodriguez-Aguayo C; Wang Y; Nick AM; Davies MA; Armaiz-Pena G; Liu J; Lutgendorf SK; Baggerly KA; Eli MB; Lopez-Berestein G; Nagrath D; Bhattacharya PK; Sood AK
J Natl Cancer Inst; 2016 Jan; 108(6):djv426. PubMed ID: 26819345
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer.
Ciucci A; Zannoni GF; Travaglia D; Petrillo M; Scambia G; Gallo D
Gynecol Oncol; 2014 Feb; 132(2):351-9. PubMed ID: 24378878
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic VDR expression as an independent risk factor for ovarian cancer.
Czogalla B; Deuster E; Liao Y; Mayr D; Schmoeckel E; Sattler C; Kolben T; Hester A; Fürst S; Burges A; Mahner S; Jeschke U; Trillsch F
Histochem Cell Biol; 2020 Oct; 154(4):421-429. PubMed ID: 32572587
[TBL] [Abstract][Full Text] [Related]
12. Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer.
Reichenbach J; Fraungruber P; Mayr D; Buschmann C; Kraus FBT; Topalov NE; Chelariu-Raicu A; Kolben T; Burges A; Mahner S; Kessler M; Jeschke U; Czogalla B; Trillsch F
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8719-8728. PubMed ID: 37131060
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer.
Abd El hafez A; El-Hadaad HA
Ann Diagn Pathol; 2014 Apr; 18(2):58-62. PubMed ID: 24342665
[TBL] [Abstract][Full Text] [Related]
14. Fibronectin and Periostin as Prognostic Markers in Ovarian Cancer.
Kujawa KA; Zembala-Nożyńska E; Cortez AJ; Kujawa T; Kupryjańczyk J; Lisowska KM
Cells; 2020 Jan; 9(1):. PubMed ID: 31936272
[TBL] [Abstract][Full Text] [Related]
15. The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.
Huang S; Qing C; Huang Z; Zhu Y
Diagn Pathol; 2016 Jun; 11(1):49. PubMed ID: 27283598
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients.
Heimes AS; Schmidt M; Jäkel J; Almstedt K; Gebhard S; Weyer-Eiberich V; Elger T; Krajnak S; Brenner W; Hasenburg A; Battista MJ
Arch Gynecol Obstet; 2019 Jan; 299(1):239-246. PubMed ID: 30357498
[TBL] [Abstract][Full Text] [Related]
17. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas.
Engqvist H; Parris TZ; Kovács A; Nemes S; Werner Rönnerman E; De Lara S; Biermann J; Sundfeldt K; Karlsson P; Helou K
BMC Cancer; 2019 Sep; 19(1):928. PubMed ID: 31533654
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
20. Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma.
Xu M; Jin T; Chen L; Zhang X; Zhu G; Wang Q; Lin Z
Gene; 2019 May; 696():63-71. PubMed ID: 30776464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
